MY ACCOUNT | NEWSLETTER |

Leptospiral infection in domestic cats


The role of domestic cats in the transmission of Leptospira is controversial, being considered either as a protective factor or a potential source of infection for humans. The aims of this study were to obtain an integrated estimate of the prevalence of leptospiral infection in domestic cats, and to characterize those individuals most susceptible to infection. 

For this systematic review and meta-analysis, researchers used five electronic databases, as well as the reference lists of eligible reports for observational studies published from 1979 to 2022. 

The literature search identified 61 eligible publications, containing 114 effect estimates. 

The overall seroprevalence was 11.7 %, the prevalence of leptospires in urine was 3.7 % and the prevalence of leptospires in kidney tissue was 12.8 %. 

There were no significant differences in the estimated prevalence after removing articles with medium risk of bias. Seroprevalence was higher in Europe when compared to Latin America and the Caribbean (P = 0.047) and showed a mild decrease over time (P = 0.023). 

Outdoor cats had almost three times greater probabilities of infection with Leptospira. No other significant effect was detected among the tested moderators or potential risk factors (P > 0.05). 

In conclusion, results suggest that feline leptospirosis should receive particular attention in veterinary care, as exposure to leptospires can occur in approximately 1 in every 10 cats, and more frequently in cats with street access. 

Domestic cats should be considered as potential Leptospira carriers when designing public health strategies for the control and prevention of leptospirosis. Further investigation is required to improve knowledge of the role of these animals in the environmental transmission cycle.

Tamara Ricardo, et al. “Leptospiral infection in domestic cats: Systematic review with meta-analysis.” Preventive Veterinary Medicine. 2023 Mar; 212:105851. doi: 10.1016/j.prevetmed.2023.105851.

Like0
Dislike0
  • Please enter a comment


Name *
Email address *
Comment *


* Required fields

Information on the processing of your personal data
We inform you that, in compliance with the provisions of current national and European regulations for the Protection of Personal Data and Services of the Information Society and Electronic Commerce, by sending us this form you are expressly giving your consent to Grupo Asís Biomedia , SL, (hereinafter, "ASIS GROUP") so that, as the person in charge, it may process your personal data in order to respond to your request for contact and information by electronic means.

Likewise, when you expressly consent, we will process your personal data to send you specialized information, newsletters, offers and exclusive promotions from GRUPO ASIS and related companies.

For the aforementioned purpose, GRUPO ASIS may transfer your data to other companies linked to GRUPO ASIS or to third party service providers for the management of electronic communications and other security services, even in cases where they are outside of the European Union, provided that they legally guarantee the adequate level of protection required by European regulations.

At any time you can withdraw the consent given and exercise the rights of access, rectification, deletion, portability of your data and limitation or opposition to its treatment by contacting GRUPO ASIS by sending an email to protecciondatos @ grupoasis.com, or by written communication to address at Centro Empresarial El Trovador, 8th floor, office I, Plaza Antonio Beltrán Martínez 1, 50002, Zaragoza (Spain), indicating in either case the Ref. Personal data and the right you exercise, as well as attaching a copy of your ID or replacement identification document.


I have read and accept the treatment of my data according to the informed purpose and according Legal notes and the Privacy Policy
I wish to receive commercial information from GRUPO ASIS and related companies



More news

Feline injection site sarcomas

Like0
Dislike0

C-reactive protein concentrations in canine acute pancreatitis

Like0
Dislike0

A retrospective clinical investigation of the safety and adverse effects of pantoprazole in hospitalized ruminants

Like0
Dislike0

Dr. Marjorie Bercier Publishes Study on Novel Diagnostic Approach for Prevalent Elephant Virus

Like0
Dislike0

FDA Approves BRAVECTO® QUANTUM (Fluralaner for Extended-Release Injectable Suspension) from Merck Animal Health

Like0
Dislike0

Newsletter

 
 

News of interest

EVENTS

Copyright © 2025 - All Rights Reserved
ISSN 2768-198X

Top